ERC-StG-2015

What is PhysCon?

The Physiological Controls Research Center (PhysCon) works on the interdisciplinary field of biomedical engineering mostly on the physiological modeling, simulation, and control domain, efficiently supporting the progress of medical science (both in terms of research and clinical practice) with actual knowledge of engineering sciences.

The most important research domains of PhysCon are connected to diabetes (artificial pancreas), hemodialysis, biostatistics (evidence-based medicine), and cancer. In regards to the latter, the PhysCon team was the recipient of the EU’s ERC StG grant.

RESEARCH DATA

Engineering Interdisciplinary Research

  •  The aim of antiangiogenic therapy is to stop the angiogenesis process (i.e. vascular system development) of the tumor; hence, to stop tumor growth.
  • Modern robust control algorithms provide automated drug administration

Present & Future

  • In the present clinical practice, there are general protocols for cancer therapies (like chemotherapy, radiotherapy)
    • these treatments have frequent and serious side effects
    • they are not cancer specific and not personalized for the patients
    • the treatment cost is low; however, the usage is non-optimized
  • Our concept: controller-based individualized treatment
    • these treatments have virtually no side effect
    • it provides personalized administration of cancer specific (antiangiogenic) drugs
    • the treatment cost is duly low due to the optimal drug administration

Model Identification & Controller Design

  • Create mathematical tumor growth model under angiogenic inhibition based on animal experiments
  • Create constant and variable quasi-continuous low-dosage therapy protocol
  • Design optimal robust control algorithms for continuous low-dosage therapy

Opening New Horizons in Cancer Treatment

  • Improve cancer therapy efficiency
  • Decrease treatment costs
  • Minimize side effects of the therapy
  • Improve the patient’s quality of life (QoL)
GENERAL INFO
  • ERC-StG-2015
  • Personalised Cancer Therapy by Model-based Optimal Robust Control Algorithm
  • Tamed Cancer
  • 01.07.2016
  • approximately EUR 1 million
  • modern robust control
  • LPV model
  • model identification
  • targeted molecular therapy
  • antiangiogenic therapy
  • Óbuda University
  • John von Neumann Faculty of Informatics
  • Prof. Dr. Levente Kovács